ERBB2 and cancer: The SEWCN use of Trastuzumab in 70% of eligible patients is consistent with other published UK results, including a recent review of the use of Trastuzumab in the North Trent Cancer Network in which 129 out of 158 HER2+ patients (69.7%) received this drug (Coulson et al, 2010).